Tag: American College Of Rheumatology

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, showed that a higher dose of pneumococcal vaccine safely and effectively improved antibody response in patients receiving rituximab for ANCA-associated vasculitis.

Study Finds Most Fetal Congenital Heart Block Screening Fails to Meet Guidelines

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, found that most echocardiography screening for fetal congenital heart block in anti-Ro- and anti-La-positive pregnancies did not follow recommended guidelines in one academic medical center.

Study Finds Spine Disease Is More Common in Chronic Recurrent Multifocal Osteomyelitis than Previously Thought

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, shows that spine disease, once considered a rarity in chronic recurrent multifocal osteomyelitis, affects as many as 10-35% of patients and is asymptomatic in one-third.

Study Finds Holding Methotrexate for One Week after Flu Vaccine May Be as Effective as a Two-Week Hold

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, showed that discontinuing methotrexate for 1 week after seasonal influenza vaccination provided the same seroprotection as a 2 week discontinuation period in patients with RA.

Study Finds Combination Therapy Does Little to Slow Spine Damage in Radiographic Axial Spondyloarthritis Patients

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, showed that combining a nonsteroidal anti-inflammatory drug and TNF inhibitor did not significantly slow radiographic spinal progression in radiographic axial spondyloarthritis patients.

Study Finds No Increased Cancer Risk in Rheumatology Patients with History of Malignancy Taking DMARDS and TNF Inhibitors

New research presented this week at ACR Convergence, the organization’s annual meeting, found no significant difference in cancer risk in patients with rheumatic disease & a history of malignancy taking biologic or targeted synthetic DMARDs compared to those treated with TNF inhibitors.

Study Finds Opioids Double Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found that adult RA patients starting opioids had twice the risk of venous thromboembolism (VTE) compared to patients starting nonsteroidal anti-inflammatory drugs (NSAIDs).

Study Links Lower Hydroxychloroquine Dose to More Hospitalizations for Systemic Lupus Erythematosus Flares

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual scientific meeting, found that the recommended weight-based or non-weight-based dose of hydroxychloroquine led to more hospitalizations for flares among patients with systemic lupus erythematosus

Primary Care Provider Training Program Improves RA Care on Navajo Nation

Research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, described a novel program that offers rheumatoid arthritis (RA) training to primary care providers in the Navajo Nation, the largest American Indian reservation in the United States.

Study Finds Early TNF Inhibitor Treatment Is Associated with Higher Heart Disease Risk in Ankylosing Spondylitis Patients — with Caveats

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found that early initiation of tumor necrosis factor (TNF) inhibitors was associated with higher risk of heart disease in patients diagnosed with ankylosing spondylitis.

Study Finds More Polyarticular JIA Patients Achieve Clinical Remission with Combined Conventional and Biologic DMARDs

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, demonstrated that polyarticular JIA patients were more likely to achieve clinical remission with a combination of conventional and biologic DMARDs compared with other treatment plans.

Study Finds NSAID Use and Age May Delay Conception in Spondyloarthritis Patients

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, showed that treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and older age were associated with longer time to conception in spondyloarthritis patients.

New Analysis Finds Belimumab Improves Cutaneous Lupus Erythematosus in Patients with or without SLE

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found that the B-cell inhibitor belimumab significantly improved cutaneous lupus erythematosus (CLE) whether or not patients also had systemic lupus erythematosus (SLE or lupus).

Study Finds Lower Risk of Severe Infection and Hospitalization with Belimumab Compared to Oral Immunosuppressants

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found that the biologic B-cell inhibitor belimumab was associated with a lower risk of severe infections and hospitalizations compared to nonbiologic immunosuppressants.

Artificial Intelligence Shows Potential for Accurate Assessment of Nailfold Changes in Systemic Sclerosis Patients

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, showed that the Vision Transformer, an open-source computer vision algorithm, could detect changes in nailfold capillaroscopy images from systemic sclerosis patients.

Researchers Develop a Risk Score to Help Detect ILD in Systemic Sclerosis Patients

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, described a first-of-its-kind validated tool to screen for systemic sclerosis-associated interstitial lung disease.

Holding Mycophenolate Mofetil for 10 Days or More May Improve COVID-19 Vaccine Response

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, demonstrated that withholding mycophenolate mofetil for 10 days significantly increased antibody response after 2 doses of COVID-19 vaccine, without a significant increase in flares.

Preterm Birth More Common in Unvaccinated Pregnant Patients with Rheumatic Disease and COVID-19

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found a greater number of preterm births in unvaccinated versus fully vaccinated pregnant patients with rheumatic disease and COVID-19.

Race, Age, Sex and Language Affected Telemedicine Use by Rheumatology Clinic Patients During COVID-19 Pandemic

November 2, 2021 sarah JonasResearch Results

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows a significant lack of fairness among telemedicine and electronic patient portals used by rheumatology clinic patients based on their race, age, sex and English language proficiency.

Patients taking Rituximab Could Benefit from Third COVID-19 Vaccine Dose

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows patients using rituximab were able to produce antibodies against COVID-19 after receiving a third vaccine dose, even if there was no development of the antibody after the first two.

Nearly One Third of Lupus Patients in One Study Had Low Responses to COVID-19 Vaccines

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that nearly 30% of patients with lupus in a multi-ethnic and multi-racial study had a low response to the new COVID-19 vaccines.

Black People with Systemic Sclerosis May Have More Severe Disease, Worse Prognosis

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that Black people living with systemic sclerosis may have more severe disease and worse prognosis than patients in other racial or ethnic groups.

Study Finds Cycling JAK Inhibitors Effective Option for Patients with Difficult-to-Treat RA

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that people with difficult-to-treat rheumatoid arthritis who do not have success with JAK inhibitor can achieve success either cycling to other JAKi or switching to a biologic drug.

Pregnant Women with Takayasu’s Arteritis and Their Babies at High Risk for Serious Complications

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that pregnant women with Takayasu’s arteritis appear to have a high prevalence of serious maternal and fetal adverse outcomes

Ultra-Low Dose Rituximab Controls Disease Activity for Most RA Patients in New Study

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows the majority of rheumatoid arthritis patients on an ultra-low dose of rituximab maintained low disease activity for up to 4 years, and rarely needed to switch to other biologic drugs.

Virtual Exercise Effective for People with Arthritis and Helps Them Stay Socially Connected Too

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, found that a virtual exercise program can be safe for people with musculoskeletal conditions, improved their health outcomes, and helped them feel more socially connected.

Higher Doses and Longer Use of Hydroxychloroquine Increase Risk of Severe Eye Complication

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that higher doses, longer duration of use, chronic kidney disease and Asian race could all be risk factors for retinopathy in people using hydroxychloroquine for rheumatoid arthritis.

Groundbreaking Study Reveals Clues to Predict Mortality in Rare VEXAS Syndrome

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows a relationship between genotype, bone marrow failure and survival in patients with the rare autoinflammatory disease VEXAS syndrome, which was only identified in 2020.

Hydroxychloroquine, Mainstay Lupus Treatment, Not Associated With Serious Cardiac Complication

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that hydroxychloroquine does not appear to be associated with QTc interval prolongation.

Platelet Inhibitors May Reduce Digital Ulcers, a Common, Painful Systemic Sclerosis Complication

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that use of platelet inhibitors could be associated with a reduction in the occurrence of digital ulcers in people with systemic sclerosis.

Study Finds COVID-19 Vaccine Not Associated with Severe Disease Flare in Patients with Rheumatic Diseases

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that the COVID-19 vaccine was not associated with severe disease flares in patients with rheumatic diseases.

Biologics Now Most Common Treatment for Children with Systemic JIA, and Many Have Excellent Results

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that biologics were the most common initial treatment prescribed to treat systemic juvenile idiopathic arthritis patients in one major registry.

Patients Reported International Hydroxychloroquine Shortages Due to COVID-19

A new study shows that patients with rheumatic diseases across Africa, Southeast Asia, the Americas and Europe had trouble filling their prescriptions of antimalarial drugs during the 2020 global coronavirus pandemic, when antimalarials were touted as a possible COVID-19 treatment. Patients who could not access their antimalarial drugs faced worse physical and mental health outcomes as a result. Details of the research was presented at ACR Convergence, the American College of Rheumatology’s annual meeting.

COVID-19 Infection Rates Low in People with Rheumatic Diseases, Most Report Mild Illness

A new study shows that the COVID-19 infection incidence has been low in people with rheumatic diseases, and most of those infected experience a mild course of illness. Additionally, fatalities have been low among rheumatic disease patients infected with COVID-19. Details of this research was presented at ACR Convergence, the American College of Rheumatology’s annual meeting.

Children with Kawasaki Disease at Higher Risk for Heart Problems More Than 10 Years After They Leave the Hospital

New research shows that children with Kawasaki Disease remain at an increased risk for cardiovascular events more than 10 years after hospitalization for their condition, highlighting the need for long-term heart disease surveillance and risk reduction strategies for these young patients. Details of the study was presented at ACR Convergence, the American College of Rheumatology’s annual meeting.

Many with Lupus at High Risk for Adverse Reactions to Pneumocystis Pneumonia Preventive Drug